Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.

In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid program pause ...

Shares of Sarepta Therapeutics rose nearly 5% in early premarket trading on Wednesday as the company prepared to present new ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the ...

Sarepta Therapeutics faces major risks in 2025 with stock collapse, halted therapies, and financial woes. Click here to read ...

Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function.

The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene ...

After three patients died, the maker of an investigational gene therapy stopped shipments of the drug after it refused to ...

Smarter design through targeted delivery and human-relevant testing can save the industry from costly safety failures.

Innovative delivery vectors and more efficient processing can cut expenses and make CGT a cost-effective option.

Aurinia Pharmaceuticals (AUPH) stock gains as the company defends its lead drug Lupkynis after a top FDA regulator linked it ...